Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer

Abstract

This study aimed to evaluate the diagnostic and prognostic significance of serum bone sialoprotein (BSP) and prostate-specific antigen doubling time (PSADT) in patients with bone metastasis (BM) from prostate cancer (PC). A total of 116 patients with PC, 120 patients with benign prostatic hyperplasia (BPH) and 120 healthy controls were enrolled in this study. PC patients were divided into bone metastasis (BM) group (n=56) and non-bone metastasis (NBM) group (n=60). Serum BSP was detected by Sandwich ELISA. Severity of bone pain was evaluated using visual analogue score (VAS). Serum f-PSA and t-PSA levels were measured by using electrochemiluminescence immunoassay (ECLIA). PSADT was calculated according to the formula: PSADT=lg(2)/[log(PSA2)-log(PSA1)]. The mean serum BSP level in PC patients with BM was significantly higher than in PC patients without BM, BPH patients and controls (P<0.001 for all). Pearson’s analysis showed that serum BSP level was positively correlated with VAS in PC patients with BM (P<0.05). Receiver operating characteristics (ROC) analysis demonstrated that BSP discriminated patients with BM from those without BM at the cutoff value of 33.26 ng/mL. The sensitivity and specificity were 78.21% and 79.28%, respectively. The optimal cutoff value of PSADT was 131 days, with sensitivity of 85.69% and specificity of 85.36%. Kaplan-Meier analysis revealed that subjects with higher BSP levels/shorter PSADT had a shorter BM-free period than those with lower BSP levels/longer PSADT. Serum BSP and PSADT are useful biomarkers for the diagnosis of BM from PC, and can be regarded as independent factors for predicting the prognosis of BM from PC. Combined determination of BSP and PSADT can improve accuracy and positive rate of BM from PC significantly.

Keywords

bone sialoprotein / prostate cancer / bone metastasis / prognosis

References

[1] BubendorfL, SchopferA, WagnerU, et al.. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol, 2000, 31(5): 578-583

[2] FisherLW, McBrideOW, TermineJD, et al.. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem, 1990, 265(4): 2347-2351

[3] RuoslahtiE. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol, 1996, 12: 697-715

[4] ZhangJH, TangJ, WangJ, et al.. Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol, 2003, 23(4): 1043-1048

[5] SchmidHP, McNealJE, StameyTA. Observations on the doubling time of prostate cancer. The use of serial prostate specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 1993, 71: 2031-2040

[6] RossPL, MahmudS, StephensonAJ, et al.. Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: value of short-term PSADT determinations. Urology, 2004, 64(2): 323-328

[7] BellahceneA, MaloujahmoumN, FisherLW, et al.. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int, 1997, 61(3): 183-188

[8] BellahceneA, Van RietI, de GreefC, et al.. Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients. Br J Haematol, 2000, 111(4): 1118-1121

[9] DielIJ, SolomayerEF, SeibelMJ, et al.. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res, 1999, 5(12): 3914-3919

[10] FedarkoNS, JainA, KaradagA, et al.. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res, 2001, 7(12): 4060-4066

[11] RobertsSG, BluteML, BergstralhEJ, et al.. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc, 2001, 76(6): 576-581